Sitagliptin Phosphate CAS No: 654671-78-0 Sitagliptin Phosphate was approved more than a decade ago primarily as a way to combat type 2 diabetes. This dipeptidyl-peptidase-4 inhibitor lowers the levels of glucose in the patient directly following a meal and can also help regulate general blood sugar levels over time. It’s usually used in combination with[…]
Sitagliptin Phosphate: A Blockbuster DPP-4 Inhibitor for Treating Type-2 Diabetes
Anti-Diabetic, Drug Research & Development API Tags: diabetes Jul 11, 2018
Brimonidine Tartrate a Safe and Effective API for Reducing Pressure Behind the Eye
Drug Research & Development API Tags: glaucomalatanoprost Jul 09, 2018
Brimonidine Tartrate CAS No: 79570-19-7 Known for treating open-angle glaucoma, brimonidine tartrate is a safe and effective API for reducing pressure behind the eye. The medication allows better drainage of fluids to both relieve patient suffering and protect eyes from further damage. High-fluid pressure can cause anything from mild nerve damage to total blindness. However,[…]
The U.S. Centers for Disease Control recently released a report that opioid-related overdoses have increased at a rate of 30% between 2016 and 2017. As the nation struggles to decide the best way to combat this epidemic, APIs like naloxone can be a light in the dark when it comes to reducing the damage done[…]
ERLANGER, Kentucky / BOCA RATON, Florida – LGM Pharma, an innovation-driven active pharmaceutical ingredient (API) company, headquartered in Erlanger, Kentucky with offices in Florida, New Jersey and Israel recently announced the appointment of Mr. Keith Lavery as chief financial officer (CFO) reporting to Dr. Prasad Raje, the CEO for LGM Pharma. In this capacity, Mr.[…]
Anidulafungin: An Effective Echinocandin Against Aggressive Fungal Infections
Anti-Fungal Tags: Amphotericin BAnidulafungin May 10, 2018
Anidulafungin CAS No: 166663-25-8 Anidulafungin is an antifungal API used to combat general yeast infections found in the blood, stomach, or esophagus and some varieties of Aspergillus. As an echinocandin, it inhibits the growth of fungal cell walls which results in either fungal cell instability or death. Echinocandins are unique in that they affect the[…]
Tacrolimus – an Effective Immunosuppressant API for a Number of Inflammatory Disorders
Immunosuppressant, OTC and Compounding Product Tags: eczemaTacrolimus Mar 30, 2018
Tacrolimus CAS No: 104987-11-3 Tacrolimus is an immunosuppressant that has been primarily used to help transplant patients accept their new organs. However, there’s more to this macrolide API than meets the eye. By inhibiting the production of T cells within the body, tacrolimus can be used to help a variety of inflammatory diseases, most notably[…]
ERLANGER, Kentucky / Boca Raton, Florida—LGM Pharma, an innovation-driven active pharmaceutical ingredient (API) company, headquartered in Erlanger, Kentucky with offices in Florida, New York and Israel recently announced that Dr. Prasad S. Raje, Ph.D. would be joining the organization as the company CEO. In that capacity, Dr. Raje will be heading up all company management[…]
Spotlight on Posaconazole: A Leading Antifungal Medication
Anti-Fungal Tags: Amphotericin BAntifungalfungusPosaconazole Mar 20, 2018
Posaconazole CAS No:171228-49-2 Posaconazole is a type of oral triazole antifungal API that has shown a high rate of efficacy for a number of fungal conditions without the risk of severe side effects. While many antifungal medications have ostensibly similar jobs, each one has their own limitations and patient disadvantages. Posaconazole was developed as an[…]
Erlanger, KY / Boca Raton, FL – LGM Pharma LLC today completed the acquisition of Zeta Pharmaceuticals’ compounding business. In Q4 2017, LGM received a significant growth capital investment from private equity firm, New Harbor Capital in Chicago. The acquisition of Zeta’s compounding business is a part of LGM’s strategy to invest in expanding its[…]
3 of the Newest API’s in the Dermatological Antifungal Segment
Anti-Fungal, EU Approved 2014, FDA Approved 2016 Tags: CrisaboroledermatitiseczemaEfinaconazolefungal infectionsPsoriasisTavaborole Jan 16, 2018
The dermatological antifungal segment has three more FDA approved options. This is good news for a specialty area that could use more diversity when it comes to treating fungal infections. Tavaborole and Efinaconazole were both approved by the FDA in 2014 to treat fungi of the nail and nailbeds, and Crisaborole was approved in 2016[…]